pharmaceutical company

Novo Nordisk

Industry Health

A foundation-influenced Danish pharmaceutical company focused on diabetes and obesity medicines, with high product utility and serious pricing and access concerns. Novo Nordisk remains weak because of documented human harm, person-dependent governance, and ideological disavowal, even where the product or service has practical value.

Why this matters: Novo Nordisk calibrates a less conventional pharma ownership structure that still uses patent power and faces affordability criticism.

Letter grade D Extractive Medium confidence (AI) Rubric gcd-rubric-v1 Last reviewed May 6, 2026

Final Score 1* D - Extractive

DEXTRACTIVE1 pts

* Tentative scaffolding score. Not human-checked or final.

Base Material30

Bonus+0

Cap41Ownership <= 4 and Governance <= 4

After Cap30

Penalties-29

Private Government badge

Novo Nordisk receives the Private Government badge because it combines large-scale private rule-setting over customers, workers, users, members, or counterparties with OpenLobby-documented lobbying of about $840K on public policy issues.

Evidence: [8]

!Not Verified

Represent this organization?

Request verification to have the evidence record checked against primary materials and organization-supplied documents. Verification does not buy a higher score; scores change only when review finds factual errors, omissions, or miscalibration.

Request verification

Evaluation Overview

D - Extractive

The score turns mainly on Product Integrity, with the largest penalty coming from Human Harm.

Strengths

Product Integrity5/5
Labor Sovereignty4/7
Loss-Bearing Fidelity4/7

Penalties

Human Harm-12
Animal Testing-6
Reversibility-5
Policy Capture-5

Evidence state

ConfidenceMedium confidence (AI)
ThoroughnessPartial (AI)
Linked claims8
Direct axis claims7
Coverage7/14

Scoring Axes

Axis	Score	Why this score
Ownership ? Control rights: shareholder-dominated at 0, worker cooperative control at 10.	3 / 10	Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. That keeps Novo Nordisk low on Ownership: decisive control remains with shareholders, private owners, executives, or state insiders rather than affected people. The value is above zero only where the linked record still shows some real function, constraint, or public value on this axis. Calibration notes Comparative anchor: Column-spectrum position: 100 scored entries below, 9 tied, 117 above on Ownership. Uncertainty Priority page: add more axis-specific research over time to make the comparative placement harder to dispute. Linked evidence Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. [1]
Governance ? Binding decision authority: centralized control at 0, democratic stakeholder control at 10.	3 / 10	Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. That keeps Novo Nordisk low on Governance: ordinary users, workers, customers, or affected communities cannot change the rules that govern them. The value is above zero only where the linked record still shows some real function, constraint, or public value on this axis. Calibration notes Comparative anchor: Column-spectrum position: 94 scored entries below, 13 tied, 119 above on Governance. Linked evidence context Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. [1] context Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. [2]
Extraction ? Surplus allocation, wage share, CEO pay ratio, margins, and structured extraction judgment.	3 / 10	Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. That keeps Novo Nordisk low on Extraction: the business model makes extraction from workers, users, suppliers, customers, or the public central rather than incidental. The value is above zero only where the linked record still shows some real function, constraint, or public value on this axis. Calibration notes Comparative anchor: Column-spectrum position: 39 scored entries below, 22 tied, 165 above on Extraction. Linked evidence context Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. [1] context Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. [2]
Labor Sovereignty ? Worker power: coercive conditions at 0, co-determination or ownership at 7. Employee dissatisfaction matters only when source-backed evidence shows concrete limits on worker agency, such as coercive scheduling, retaliation, wage theft, harassment, unsafe conditions, suppression of worker voice, or extreme turnover.	4 / 7	Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. That places Novo Nordisk in the middle of Labor Sovereignty: workers or participants have some protection or agency, but not enough binding power to control the relationship. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 112 scored entries below, 39 tied, 75 above on Labor Sovereignty. Linked evidence context Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. [1] context Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. [2]
Solidarity with the Unemployed ? Treatment of exits and nonworkers, including severance, redeployment, and non-competes.	3 / 7	Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. That places Novo Nordisk in the middle of Solidarity with the Unemployed: some access, severance, retraining, openness, or mutual-aid value is present, but it is not central or durable. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 81 scored entries below, 45 tied, 100 above on Solidarity with the Unemployed. Linked evidence context Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. [1] context Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. [2]
Loss-Bearing Fidelity ? Willingness to absorb costs to preserve values, workers, users, and public obligations.	4 / 7	Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. That places Novo Nordisk in the middle of Loss-Bearing Fidelity: there is some willingness to preserve obligations, but the record still leaves meaningful risk-shifting concerns. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 88 scored entries below, 30 tied, 108 above on Loss-Bearing Fidelity. Linked evidence context Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. [1] context Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. [2]
Market Conduct ? Pricing fairness, switching costs, lock-in, and rent extraction.	2 / 5	Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. That places Novo Nordisk in the middle of Market Conduct: the product has real value but still uses meaningful lock-in, gatekeeping, market power, or dependency. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 31 scored entries below, 22 tied, 173 above on Market Conduct. Linked evidence context Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. [1] context Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. [2]
Product Integrity ? Preservation of quality rather than degradation for monetization.	5 / 5	Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. That places Novo Nordisk high on Product Integrity: the core offering is genuinely useful and comparatively less dependent on traps, degradation, or harmful dependencies. A still-higher or maximum value requires stronger proof that this structure is durable, broad, and not merely discretionary. Calibration notes Comparative anchor: Column-spectrum position: 134 scored entries below, 92 tied, 0 above on Product Integrity. Uncertainty Priority page: add more axis-specific research over time to make the comparative placement harder to dispute. Linked evidence Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. [2]
Scale Integrity ? Whether growth improves or degrades fairness and accountability.	3 / 5	Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. That places Novo Nordisk in the middle of Scale Integrity: scale brings useful reach but also weakens accountability, transparency, or local constraint. The value stays below the top tier because the linked record does not show full democratic control, non-extractive lock-in, or complete stakeholder protection on this axis. Calibration notes Comparative anchor: Column-spectrum position: 50 scored entries below, 58 tied, 118 above on Scale Integrity. Linked evidence context Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company. [1] context Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used. [2]

Penalties

Penalty	Applied	Why this penalty
Reversibility ? Applied when positive conduct depends on current living leaders, founders, family owners, or other person-contingent governance rather than durable structure. Range: -5 to 0.	-5	Novo Nordisk positive conduct depends on foundation-linked governance, corporate leadership, patent strategy, pricing policy, and regulation rather than structurally democratic patient, worker, or public control. Novo Nordisk positive conduct depends on foundation-linked governance, corporate leadership, patent strategy, pricing policy, and regulation rather than structurally democratic patient, worker, or public control. That warrants a severe Reversibility penalty because favorable conduct depends on current people or discretionary leadership rather than locked stakeholder structure. The value is near the floor because the conduct appears central, large-scale, repeated, or institutionally powerful rather than incidental. Calibration notes Comparative anchor: Column-spectrum position: 0 scored entries below, 95 tied, 131 above on Reversibility. Linked evidence Novo Nordisk positive conduct depends on foundation-linked governance, corporate leadership, patent strategy, pricing policy, and regulation rather than structurally democratic patient, worker, or public control. [3]
Human Harm ? Severity, scale, culpability, vulnerable targets, willful reoffense, reputation laundering, pattern escalation, and time decay. Range: -20 to 0.	-12	Novo Nordisk insulin and diabetes-drug pricing scrutiny is relevant to the human-harm penalty because affordability affects access to medically necessary treatment. Novo Nordisk insulin and diabetes-drug pricing scrutiny is relevant to the human-harm penalty because affordability affects access to medically necessary treatment. That warrants a substantial Human Harm penalty because ordinary operation, documented misconduct, or institutional power creates serious injury, deprivation, abuse, or foreseeable human damage. The value is substantial but not at the floor because the linked record shows serious conduct without the strongest aggravating factors on this axis. Calibration notes Comparative anchor: Column-spectrum position: 20 scored entries below, 3 tied, 203 above on Human Harm. Linked evidence Novo Nordisk insulin and diabetes-drug pricing scrutiny is relevant to the human-harm penalty because affordability affects access to medically necessary treatment. [4]
Policy Capture ? Private-interest attempts to bend law, regulation, subsidies, taxes, enforcement, trade, labor, safety, competition, environmental, healthcare, housing, surveillance, civil-liberties, or consumer policy against workers, customers, citizens, affected communities, or ecological life. Public-interest advocacy is not penalized merely because it is lobbying. Range: -15 to 0.	-5	OpenLobby records NOVO NORDISK, INC. lobbying on healthcare and budget with about $840K in spending across 18 filings; the reviewed filings document private institutional lobbying over public rules rather than a public-interest advocacy role. OpenLobby records NOVO NORDISK, INC. lobbying on healthcare and budget with about $840K in spending across 18 filings; the reviewed filings document private institutional lobbying over public rules rather than a public-interest advocacy role. That warrants a limited Policy Capture penalty because private institutional pressure is being applied to public rules while affected people cannot democratically govern that agenda. The value is limited because the linked record shows a real problem but not one that dominates the profile on this axis. Linked evidence OpenLobby records NOVO NORDISK, INC. lobbying on healthcare and budget with about $840K in spending across 18 filings; the reviewed filings document private institutional lobbying over public rules rather than a public-interest advocacy role. [6]
Animal Testing ? Direct animal testing, contract animal testing, animal-testing-dependent product development, or business lines where current safety/regulatory approval normally relies on animal experiments. Stronger penalties apply where animal testing is core, repeated, non-optional, or avoidable; documented cruelty-free or non-animal methods reduce or eliminate the penalty. Range: -8 to 0.	-6	Pharmaceutical, medical-product, or drug-development business models remain structurally tied to animal-testing systems in current regulated product development. Linked evidence Novo Nordisk has drug/medical product development animal-testing exposure based on its listed business model and current profile description: A foundation-influenced Danish pharmaceutical company focused on diabetes and obesity medicines, with high product utility and serious pricing and access concerns. Novo Nordisk remains weak because of documented human h… [7]
Ideological Disavowal ? Concealed ideology presented as neutrality, expertise, professional necessity, public-service administration, market inevitability, or non-ideological common sense while exercising power. Range: -3 to 0.	-1	Novo Nordisk's public framing is assessed as ideological-disavowal evidence because Novo Nordisk shows bounded neutrality theater: some contested choices are softened through expertise,… Novo Nordisk's public framing is assessed as ideological-disavowal evidence because Novo Nordisk shows bounded neutrality theater: some contested choices are softened through expertise, public-interest, professional, market, safety, or institutional language, but the record does not show dominant concealment of standpoint. That warrants a limited Ideological Disavowal penalty because the institution presents situated, contested choices as neutrality, expertise, inevitability, safety, or common sense. The value is limited because the linked record shows a real problem but not one that dominates the profile on this axis. Calibration notes Comparative anchor: Ideological Disavowal 0 to -3 recalibration: 0 for explicit standpoint or no penalty-level neutrality theater; -1 for bounded softening of contested choices; -2 for strong neutrality theater by a powerful institution; -3 for major gatekeeping or coercive power presented as neutral, necessary, objective, or non-ideological. Uncertainty This recalibration uses public self-presentation and profile evidence; later review should add direct language-analysis evidence for high-impact institutions. Linked evidence Novo Nordisk's public framing is assessed as ideological-disavowal evidence because Novo Nordisk shows bounded neutrality theater: some contested choices are softened through expertise, public-interest, professional, market, safety, or institutional language, but the record does not show dominant concealment of standpoint. [5]

Bonus Credits

No bonus credits applied in this version.

Confidence Basis

Confidence is computed from the evidence trail and review state, not typed into the profile by hand.

Medium 73/100

7 verified linked claims 7 direct axis claims 0 disputed claims 7/14 components covered

This confidence label measures the source-backed evidence trail. AI-scaffolded scores remain tentative until human review.

Claim confidence 17/20

7 verified linked claims

Source quality 13/18

Best source per verified claim, weighted by institutional reliability

Direct axis-specific claims 9/18

7 direct claims across 14 active components

Dispute load 12/12

0 disputed claims on this entity

Recency 10/10

Newest accepted timestamp: May 13, 2026

Reviewer status 7/12

Human-reviewed components score higher than AI scaffolding

Component coverage 5/10

7/14 evidence-bearing components have direct support

Evidence State

Profile stateAI draft / human-pending

VerificationUnverified

ConfidenceMedium confidence (AI)

ThoroughnessPartial (AI)

Correction routeUse “Challenge this rating” for factual errors, missing counterevidence, source problems, or calculation mistakes.

Company responseCompany representatives can submit source-backed corrections; payment never changes scores or reviewer authority.

Claims and Sources

Claims are the evidence record. Each claim needs a source link, axis category, status, confidence level, and timestamp before it can support a score.

* Tentative scaffolding score. Not human-checked or final.

1Novo Nordisk publishes investor materials and describes a governance structure influenced by Novo Holdings and the Novo Nordisk Foundation while remaining a public company.

Ownership Verified High confidence AI-generated / human-pending May 6, 2026

AI scaffold

Novo Nordisk ownership structureOfficial self-description · 68%

2Novo Nordisk develops and sells diabetes, obesity, and related medicines that can provide high direct health value when accessible and appropriately used.

Product Integrity Verified High confidence AI-generated / human-pending May 6, 2026

AI scaffold

Novo Nordisk therapeutic areasGeneral web source · 58%

3Novo Nordisk positive conduct depends on foundation-linked governance, corporate leadership, patent strategy, pricing policy, and regulation rather than structurally democratic patient, worker, or public control.

Reversibility Verified Medium confidence AI-generated / human-pending May 6, 2026

AI scaffold

Novo Nordisk ownership structureOfficial self-description · 68%

4Novo Nordisk insulin and diabetes-drug pricing scrutiny is relevant to the human-harm penalty because affordability affects access to medically necessary treatment.

Human Harm Verified High confidence AI-generated / human-pending May 6, 2026

AI scaffold

FTC prescription drug middlemen reportPrimary public record · 100%

5Novo Nordisk's public framing is assessed as ideological-disavowal evidence because Novo Nordisk shows bounded neutrality theater: some contested choices are softened through expertise, public-interest, professional, market, safety, or institutional language, but the record does not show dominant concealment of standpoint.

Ideological Disavowal Verified Medium confidence AI-generated / human-pending May 9, 2026

AI scaffold

Novo Nordisk official siteGeneral web source · 58%
Novo Nordisk ownership structureOfficial self-description · 68%
Novo Nordisk therapeutic areasGeneral web source · 58%

6OpenLobby records NOVO NORDISK, INC. lobbying on healthcare and budget with about $840K in spending across 18 filings; the reviewed filings document private institutional lobbying over public rules rather than a public-interest advocacy role.

Policy Capture Verified Medium confidence AI-generated / human-pending May 11, 2026

AI scaffold

OpenLobby — NOVO NORDISK, INC. lobbying profileGeneral web source · 58%

7Novo Nordisk has drug/medical product development animal-testing exposure based on its listed business model and current profile description: A foundation-influenced Danish pharmaceutical company focused on diabetes and obesity medicines, with high product utility and serious pricing and access concerns. Novo Nordisk remains weak because of documented human h…

Animal Testing Verified High confidence Human-reviewed May 11, 2026

Novo Nordisk public siteGeneral web source · 58%
FDA: Animal Welfare, Testing and Research of FDA-Regulated ProductsPrimary public record · 100%

8Novo Nordisk receives the Private Government badge because it combines large-scale private rule-setting over customers, workers, users, members, or counterparties with OpenLobby-documented lobbying of about $840K on public policy issues.

Private Government Verified Medium confidence AI-generated / human-pending May 11, 2026

AI scaffold

OpenLobby — NOVO NORDISK, INC. lobbying profileGeneral web source · 58%

Alternatives

Competitors

AGOOD66 Patient Advocate Foundation nonprofit patient case-management and financial-aid resource · United States AGOOD57 Outside In youth, health, housing, and harm-reduction nonprofit · Oregon, Pacific Northwest AGOOD54 Federally Qualified Health Centers publicly supported community health-center system · United States AGOOD53 OpenNotes academic healthcare-transparency initiative · United States AGOOD50 CPESN USA network of independent community pharmacies · United States BQUALIFIED49 Civica Rx nonprofit generic medicine company · United States BQUALIFIED43 Planned Parenthood nonprofit reproductive and sexual healthcare federation · United States CPERFORMATIVE41 En-Vision America / ScriptAbility accessible prescription-labeling company · United States

Help Improve This Profile

Submit source-backed evidence or challenge a specific claim, source, axis value, or calculation below.

How This Page Is Maintained

Evidence comes in through contributors, is checked by verifiers, and is synthesized by reviewers. Founder authority remains narrow and visible; scores recalculate when verified claims or the rubric change.

Civic Note

Incorporation, limited liability, market access, and other institutional privileges are public grants. Good Companies Directory treats those privileges as conditional on accountability to workers, users, communities, and the public.

Submit evidence for Novo Nordisk Add one source-backed fact for review.

Challenge this rating Point to a specific score, claim, source, or calculation problem.

Audit Log

Recent public changes for this company or group. The full audit log is part of the Transparency record.

May 6, 2026 at 12:00 AM UTC ai-scaffolding

View Full Audit Log